Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial

The Lancet

Volumn 388, Issue 10055, 2016, Pages 2004-2014

  Mulvenna, Paula ^a   Nankivell, Matthew ^b   Barton, Rachael ^c   Faivre Finn, Corinne ^d   Wilson, Paula ^e   McColl, Elaine ^f   Moore, Barbara ^g   Brisbane, Iona ^h   Ardron, David ⁱ   Holt, Tanya ^j,k   Morgan, Sally ^l   Lee, Caroline ^m   Waite, Kathryn ⁿ   Bayman, Neil ^d   Pugh, Cheryl ^b   Sydes, Benjamin ^b   Stephens, Richard ^b   Parmar, Mahesh K ^b   Langley, Ruth E ^b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CASTLE HILL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g South East Wales Cancer Network   (United Kingdom)

^h BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

ⁱ Patient Representative   (United Kingdom)

^j Trans Tasman Radiation Oncology Group   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^m WESTON PARK HOSPITAL   (United Kingdom)

ⁿ QUEEN ELIZABETH HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD; BONE MARROW; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; HAIR LOSS; HEART DISEASE; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; KIDNEY DISEASE; LINEAR ACCELERATOR; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SCALP PRURITUS; SIDE EFFECT; SOFT TISSUE DISEASE; STEREOTACTIC TREATMENT; STOMACH DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT OBSTRUCTION; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VISUAL DISORDER; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; LUNG TUMOR; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEXAMETHASONE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84992597824     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30825-X     Document Type: Article

References (42)

1. 1 Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. 2 Law, A, Karp, DD, Dipetrillo, T, Daly, BT, Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer 92 (2001), 160–164.
3. 3 Barnholtz-Sloan, JS, Sloan, AE, Davis, FG, Vigneau, FD, Lai, P, Sawaya, RE, Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 (2004), 2865–2872.
4. 4 Chen, AM, Jahan, TM, Jablons, DM, Garcia, J, Larson, DA, Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 109 (2007), 1668–1675.
5. 5 Stuschke, M, Eberhardt, W, Pöttgen, C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17 (1999), 2700–2709.
6. 6 Borgelt, B, Gelber, R, Kramer, S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6 (1980), 1–9.
7. 7 Borgelt, B, Gelber, R, Larson, M, Hendrickson, F, Griffin, T, Roth, R, Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7 (1981), 1633–1638.
8. 8 Gaspar, L, Scott, C, Rotman, M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37 (1997), 745–751.
9. 9 Priestman, TJ, Dunn, J, Brada, M, Rampling, R, Baker, PG, Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol (R Coll Radiol) 8 (1996), 308–315.
10. 10 Sperduto, PW, Chao, ST, Sneed, PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77 (2010), 655–661.
11. 11 Brown, PD, NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol, 33(suppl 15), 2015, LBA4 (abstr).
12. 12 Lee, SM, Lewanski, CR, Counsell, N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst, 106, 2014, dju151.
13. 13 Mehta, MP, Shapiro, WR, Phan, SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73 (2009), 1069–1076.
14. 14 Chao, JH, Phillips, R, Nickson, JJ, Roentgen-ray therapy of cerebral metastases. Cancer 7 (1954), 682–689.
15. 15 Order, SE, Hellman, S, Von Essen, CF, Kligerman, MM, Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology 91 (1968), 149–153.
16. 16 Tsao, MN, Lloyd, N, Wong, RK, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev, 4, 2012 CD003869.
17. 17 Horton, J, Baxter, DH, Olson, KB, The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 111 (1971), 334–336.
18. 18 Rades, D, Schild, SE, Lohynska, R, Veninga, T, Stalpers, LJ, Dunst, J, Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer 110 (2007), 1077–1082.
19. 19 Tsao, MN, Rades, D, Wirth, A, et al. International practice survey on the management of brain metastases: Third International Consensus Workshop on Palliative Radiotherapy and Symptom Control. Clin Oncol (R Coll Radiol) 24 (2012), e81–e92.
20. 20 American College of Radiology. ACR Appropriateness Criteria, Multiple Brain Metastases. https://acsearch.acr.org/docs/69383/narrative/, 2014 (accessed Jan 27, 2016).
21. 21 Andrews, DW, Scott, CB, Sperduto, PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (2004), 1665–1672.
22. 22 Langer, CJ, Mehta, MP, Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23 (2005), 6207–6219.
23. 23 Mehta, MP, Rodrigus, P, Terhaard, CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21 (2003), 2529–2536.
24. 24 Soffietti, R, Costanza, A, Laguzzi, E, Nobile, M, Ruda, R, Radiotherapy and chemotherapy of brain metastases. J Neurooncol 75 (2005), 31–42.
25. 25 Kaal, EC, Niel, CG, Vecht, CJ, Therapeutic management of brain metastasis. Lancet Neurol 4 (2005), 289–298.
26. 26 Khuntia, D, Brown, P, Li, J, Mehta, MP, Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24 (2006), 1295–1304.
27. 27 Sneed, PK, Larson, DA, Wara, WM, Radiotherapy for cerebral metastases. Neurosurg Clin N Am 7 (1996), 505–515.
28. 28 Mehta, M, The dandelion effect: treat the whole lawn or weed selectively?. J Clin Oncol 29 (2011), 121–124.
29. 29 Zimm, S, Wampler, GL, Stablein, D, Hazra, T, Young, HF, Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48 (1981), 384–394.
30. 30 Lin, X, DeAngelis, LM, Treatment of brain metastases. J Clin Oncol 33 (2015), 3475–3484.
31. 31 Coia, LR, Aaronson, N, Linggood, R, Loeffler, J, Priestman, TJ, A report of the consensus workshop panel on the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23 (1992), 223–227.
32. 32 Hoskin, PJ, Brada, M, Second Workshop on Palliative Radiotherapy and, Symptom Control. Radiotherapy for brain metastases. Clin Oncol (R Coll Radiol) 13 (2001), 91–94.
33. 33 EuroQol, G, EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
34. 34 Gerrard, GE, Prestwich, RJ, Edwards, A, et al. Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 15 (2003), 422–428.
35. 35 Langley, RE, Stephens, RJ, Nankivell, M, et al. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?. Clin Oncol (R Coll Radiol) 25 (2013), e23–e30.
36. 36 Billingham, LJ, Abrams, KR, Simultaneous analysis of quality of life and survival data. Stat Methods Med Res 11 (2002), 25–48.
37. 37 Lutterbach, J, Bartelt, S, Stancu, E, Guttenberger, R, Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3. Radiother Oncol 63 (2002), 339–345.
38. 38 Mulvenna, PM, The management of brain metastases in patients with non-small cell lung cancer—is it time to go back to the drawing board?. Clin Oncol (R Coll Radiol) 22 (2010), 365–373.
39. 39 Nieder, C, Nestle, U, Motaref, B, Walter, K, Niewald, M, Schnabel, K, Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive patitioning analysis (RPA) classes?. Int J Radiat Oncol Biol Phys 46 (2000), 297–302.
40. 40 Taphoorn, MJ, Claassens, L, Aaronson, NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46 (2010), 1033–1040.
41. 41 Owen, S, Souhami, L, The management of brain metastases in non-small cell lung cancer. Front Oncol, 4, 2014, 248.
42. 42 Yamamoto, M, Serizawa, T, Shuto, T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15 (2014), 387–395.